Gateway Investment Advisers LLC Has $1.92 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Gateway Investment Advisers LLC has reduced its stake in Alnylam Pharmaceuticals by 10%, owning 5,889 shares valued at approximately $1.92 million after selling 651 shares in Q2.
• Directors of Alnylam Pharmaceuticals, including Michael W. Bonney and CEO Yvonne Greenstreet, sold significant shares recently, leading to decreases in their personal holdings by over 40% and 11%, respectively.
• Analyst ratings for Alnylam Pharmaceuticals have been positive, with firms like BMO Capital Markets and Citigroup raising their price targets and maintaining buy ratings, reflecting strong investor interest.

Gateway Investment Advisers LLC reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,889 shares of the biopharmaceutical company's stock after selling 651 shares during the quarter. Gateway Investment Advisers LLC's holdings in Alnylam Pharmaceuticals were worth $1,920,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at about $27,000. Park Square Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $28,000. Whipplewood Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Finally, Washington Trust Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 61 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ALNY shares. Morgan Stanley lifted their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Truist Financial began coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $385.00 target price on the stock. UBS Group lifted their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Oppenheimer raised Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a report on Monday, August 4th. Finally, Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $439.58.

Alnylam Pharmaceuticals Stock Up 0.3%

NASDAQ:ALNY traded up $1.39 on Friday, hitting $453.56. 1,713,315 shares of the company's stock traded hands, compared to its average volume of 1,073,061. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21. The firm has a 50-day moving average price of $415.05 and a 200-day moving average price of $324.19. The company has a market cap of $59.45 billion, a PE ratio of -183.63 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the previous year, the business posted ($0.13) EPS. The business's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the sale, the chief executive officer directly owned 56,221 shares in the company, valued at $25,483,292.67. The trade was a 11.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the sale, the executive vice president owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. This represents a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 75,594 shares of company stock worth $33,968,256 over the last quarter. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.